The risk of recurrent ischemic stroke can be reduced by managing modifiable risk factors and instituting a regimen of mechanism-specific secondary stroke prevention. Strategies for secondary ...

Researchers sought to determine the relationship between food security and outcomes in hemorrhagic and ischemic stroke patients.

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic (clot-caused) stroke without raising bleeding concerns, according to a preliminary ...

Transient Ischemic Attack, also known as "mini-stroke", occurs when there is a temporary blockage of blood flow to the brain. The American Stroke Association says that the clot usually dissolves on ...

Guideline endorses intravenous tenecteplase or alteplase within the 4.5-hour thrombolytic treatment window. (HealthDay News) — In a guideline issued by the American Heart Association/American Stroke ...

The factor XIa inhibitor, asundexian (Bayer), has finally achieved the holy grail of reducing thrombotic events without increasing bleeding. In the OCEANIC-STROKE trial, conducted in patients with ...

Heart Health Month is wrapping up, but the fight against stroke goes on every day.

Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting within 48 hours of stroke symptoms, had better recovery than patients who ...

For patients with non-large vessel occlusion, acute ischemic stroke and salvageable brain tissue, intravenous tenecteplase administered 4.5 to 24 hours after stroke onset is associated with a higher ...

NEW ORLEANS, LA—Adding the factor XIa inhibitor asundexian (Bayer) to antiplatelet therapy tops antiplatelet therapy alone for preventing ischemic strokes in patients with acute noncardioembolic ...

About The Study: Among patients with non–large vessel occlusion acute ischemic stroke and salvageable brain tissue, intravenous tenecteplase, a modified human tissue plasminogen activator, ...